To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data for infliximab by key baseline characteristics, with matching weights determined by logistic regression, and used to recalculate American College of Rheumatology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab. At week 54/52, ACR 20/50 responses were higher for secukinumab 300 mg than infliximab. Conclusion: In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving infliximab.
FUTURE 3 had a similar design to that of FUTURE 2 (and importantly used the approved dosages of secukinumab 150 and 300 mg). Secukinumab was administered subcutaneously using an autoinjector in FUTURE 3, whereas in FUTURE 2 a prefilled syringe was used. The potential for a small effective sample size (ESS) following matching is a known limitation of MAIC [12] ; therefore, to maximize the ESS in our study, we decided to use pooled IPD from the FUTURE 2 and FUTURE 3 studies. Pooling IPD to match to aggregate data is a valid methodology to increase the potential ESS in a MAIC [13, 21] .
Studies included FUTURE 2 [9] and FUTURE 3 [10] were both Phase III RCTs (Figure 1 ). In FUTURE 2, patients were randomized 1:1:1:1 to receive subcutaneous secukinumab 75, 150 or 300 mg, or placebo [9] . In FUTURE 3, patients were randomized 1:1:1 to receive subcutaneous secukinumab 150 or 300 mg, or placebo. Patients who had previously experienced TNFi incomplete response (TNFi-IR) were included, with up to three treatment failures being admissible. IMPACT 2 was also a Phase III RCT (Figure 1 ) [19] . Patients were randomized 1:1 to receive intravenous infusions of either infliximab 5 mg/kg or placebo. The primary end point was achievement of an ACR 20 response at week 14 [19] .
Selection of baseline characteristics for matching
The selection of baseline characteristics for matching (including prognostic variables and effect modifiers) has been described previously [20] . Two scenarios were developed that differed in the combination of included matching variables. First, a principal analysis (Table 1) included established prognostic variables reported in previous MAICs in PsA [18, 20] , but incorporated one additional parameter (TNFi-IR), identified by logistic regression analysis as a key effect modifier, as detailed in our previous study [20] . Previous TNFi exposure is also likely to be an effect modifier for infliximab: it has been established that patients with PsA who switch between TNFi therapies have lower ACR responses with subsequent TNFis than TNFi-naive patients [22] [23] [24] [25] .
A sensitivity analysis ( Supplementary Table 3 ) was performed, and included all matching variables used in the principal analysis plus three additional important clinical characteristics to increase the matching stringency: PsA disease duration (time since diagnosis), swollen joint count (SJC) and baseline CRP levels.
Matching & adjusting individual patient data to published aggregate data & comparing outcomes
The MAIC matching process is shown in Figure 2 . IPD from the pooled secukinumab 150 and 300 mg arms of the FUTURE 2/3 RCTs were weighted to match the selected patient baseline characteristics for the infliximab arm of IMPACT 2, for which aggregate data were taken from the trial publication [19] . Placebo arms were also matched. The methodology was based on Signorovitch et al. [26] and subsequent publications [16, 27, 28] , and methodological guidelines were followed [14] . After this matching process, the weighted mean baseline characteristics of the pooled FUTURE 2/3 populations were identical to those reported for IMPACT 2. Consequently, the matching resulted in a lower ESS for the FUTURE 2/3 arms. SAS version 9.4 and R version 3.2.1 were used for the analysis. After matching, outcomes in the reweighted FUTURE 2/3 population were compared with outcomes reported in IMPACT 2. Given that the comparison was conducted in a population matched to IMPACT 2, the target population or clinical context, of our comparison was restricted to TNFi-naive patients with characteristics similar to those in the IMPACT 2 trial.
Analyses

Reporting of missing data
In IMPACT 2, all published outcomes included in this MAIC were from the intention-to-treat population, as were those from FUTURE 2/3. All missing ACR data were handled using nonresponder imputation [19] , except at week 54/52 when missing data were based on observed data. Scores from the 36-item Short-Form health hurvey (SF-36) were derived from the secukinumab arms using last observation carried forward for missing data at all time points to match the available data from IMPACT 2. To ensure the robustness of these analyses, ACR 20 responses and odds ratios (ORs) at week 54/52 were also estimated by alternative imputation methods. Given that IMPACT 2 outcome data at week 6 were reported in graphs only, specific software (DigitizeIt, Braunschweig, Germany) was used for data extraction. Outcomes ACR 20/50/70 responses and SF-36 scores were selected for comparison in line with the Outcomes Measures in Rheumatology (OMERACT) [29] and GRAPPA [30] guidelines on outcome measures that should be included in RCT datasets in PsA [29] . Comparisons were made between outcomes at the closest available time points in the two trials. ACR response criteria encompass a number of disease domains, including tender joint count and SJC, patient global assessment, pain and physical function, and acute phase response, and therefore represent a stringent outcome measure.
Health-related quality of life was measured using SF-36, which comprises eight domains that can be aggregated into two summary measures: the physical (PCS) and mental component summary (MCS) scores. The PCS is calculated by weighting the four physical and vitality domains positively and the remaining three mental domains negatively. To calculate the MCS, the four mental domains are positively weighted and the physical domains are negatively weighted. These are presented as mean changes from baseline (CFBs).
Placebo-adjusted & non-placebo-adjusted outcome comparisons
Placebo-adjusted comparisons (anchored) were only possible until week 16, as all patients randomized to placebo could potentially receive active rescue treatment from week 16 onward in all three trials. Owing to the lack of placebo as common comparator after week 16, non-placebo-adjusted (unanchored) outcomes from the infliximab arm of IMPACT 2 were directly compared with recalculated outcomes from the secukinumab 150 and 300 mg pooled arms of FUTURE 2/3.
Pairwise comparisons
ACR responses -For the analysis at weeks 6/8 and 14/16 (placebo-adjusted), ORs for the secukinumab arm versus the placebo arm in the reweighted FUTURE 2/3 population were derived from a logistic regression model by using generalized estimating equations with robust standard errors, as recommended by Signorovitch et al. and the National Institute for Health and Care Excellence (NICE) guidance on MAIC methodology [14, 26] . Generalized estimating equations were fitted using PROC GENMOD in SAS. These placebo-adjusted OR values were used to estimate the comparative effectiveness of secukinumab and infliximab using the method of Bucher et al. [31] . By using linear predictor scales such as ORs instead of comparing natural outcome scales such as ACR 20 responses, we complied with a mandatory requirement of NICE [14, 15] .
For non-placebo-adjusted comparisons, standard errors for OR values were estimated based on the information provided by a 2 × 2 contingency table that showed outcomes in the infliximab arm of the IMPACT 2 trial and outcomes in the recalculated pooled secukinumab arm of FUTURE 2/3.
Psoriasis area and severity index (PASI) outcomes -We did not report PASI data because baseline characteristic data for the IMPACT 2 trial psoriasis subgroup were not available. This meant that uncontrolled imbalances could persist postmatching. It is also worth noting that PASI data were collected only in a subgroup of patients in both RCT populations (patients with psoriasis affecting ≥3% body surface area); consequently, missing data in the non-PASI-matched population could further compound this study bias.
SF-36 summary scores -A 95% CI around mean changes in scores for patients in the infliximab arm of the IMPACT 2 trial was estimated using the normal approximation. The p-values for the differences in mean change scores between secukinumab and infliximab were calculated using a Z-statistic, which divides the difference in mean changes in scores by the combined standard error.
Results
Principal analysis
Matching baseline characteristics Table 1 shows the baseline characteristics of patients in the pooled FUTURE 2/3 population before matching (secukinumab 150 mg, n = 238; secukinumab 300 mg, n = 239; placebo, n = 235) and after matching to the IMPACT 2 infliximab (n = 100) and placebo (n = 100) arms. Before matching, a key difference between patient populations was the proportion who were TNFi-naive (secukinumab 150 mg, 66.0%; secukinumab 300 mg, 67.8%; placebo [FUTURE 2/3], 66.4%; infliximab, 100.0%; placebo [IMPACT 2], 100.0% [p < 0.0001]). After matching, all patients were TNFi-naive. Similar observations were made for all matching variables in the principal (Table 1 ) and sensitivity analyses ( Supplementary Table 3 ). Therefore, although there was heterogeneity in the patient populations between FUTURE 2/3 and IMPACT 2 before matching, parameters were more similar after matching, with a reduced ESS for FUTURE 2/3 (secukinumab 150 mg, 84; secukinumab 300 mg, 70; placebo, 41). Table 2 show ACR 20/50/70 responses for secukinumab 150 mg and infliximab 5 mg/kg, for both placebo-adjusted (weeks 6/8 and 14/16) and non-placebo-adjusted (weeks 24 and 54/52) time points. There were no differences in ACR responses between secukinumab 150 mg and infliximab at weeks 6/8 and 14/16 (both placebo-adjusted). At week 24, secukinumab 150 mg was associated with higher ACR 20 responses than infliximab (OR [95% CI]: 2.31 [1.24-4.29] ; p = 0.008). Week 54/52 non-placebo-adjusted ACR 20 responses were also higher with secukinumab 150 mg than infliximab (OR [95% CI]: 3.03 [1.52-6.04]; p = 0.002).
ACR responses
Figures 3 and 4 and
As shown in Figures 3 and 4 and Table 2 , there was no evidence of differences in ACR 20/50/70 responses between secukinumab 300 mg and infliximab at weeks 6/8 and 14/16 (both placebo-adjusted) and at week 24 (nonplacebo-adjusted). At week 54/52, non-placebo-adjusted ACR 20/50 responses were higher with secukinumab 300 mg than infliximab (OR [95% CI]: 2.72 [1.33-5.57]; p = 0.006, and 2.69 [1.41-5.11]; p = 0.003, respectively). These observations were unchanged when alternative imputation methods were applied ( Supplementary Table 4 ). Table 2 shows ORs and p-values for all ACR comparisons, including interpretations using the p-value range between 0.1 and 0.001. Week 6/8
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Odds ratio 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 Week 52 FUTURE 2/3 secukinumab intent-to-treat population (observed values) was compared with week 54 IMPACT 2 infliximab intent-to-treat population (missing equals failure/missing values excluded). In FUTURE 2/3, patients receiving placebo who did not achieve ≥20% improvement compared with baseline in TJC or SJC by week 16 were rerandomized 1:1 to secukinumab 150 or 300 mg; those who did achieve this response were rerandomized 1:1 at week 24. In IMPACT 2, patients receiving placebo who had <10% improvement from baseline in both SJC and TJC at week 16 received infliximab 5 mg/kg. Patients randomized to infliximab 5 mg/kg who had <20% improvement from baseline in the combined number of SJC and TJC had their infliximab dose increased to 10 mg/kg at weeks 38 and 46; 15 patients received an uptitration in their dose of infliximab from 5 to 10 mg/kg. SJC: Swollen joint count; TJC: Tender joint count. (below) and should therefore be considered with caution. There were no differences in MCS scores at any time points in the principal analysis. These observations were consistent when data were interpreted using the p-value range between 0.1 and 0.001 (Table 3) .
Odds ratio
Changes in SF-36 PCS & MCS scores
Sensitivity analysis Matching baseline characteristics
The sensitivity analysis matched data using the same parameters as the principal analysis, with addition of PsA disease duration and baseline SJC and CRP levels, as shown in Supplementary Table 3 . The ESSs for FUTURE 2/3 after matching were 49 for secukinumab 150 mg, 32 for secukinumab 300 mg and 27 for placebo.
ACR responses
The results of the sensitivity analysis were consistent with those of the principal analysis (Supplementary Figure  2and Supplementary Table 5 ). ACR 20 responses were higher with secukinumab 150 mg than infliximab at weeks 24 and 54/52 during the non-placebo-adjusted period (OR [95% CI]: 3.03 [1.39-6.63]; p = 0.005, and 3.87 [1.60-9.36]; p = 0.003, respectively). ACR 20 and ACR 50 responses were higher with secukinumab 300 mg than infliximab at week 54/52 (OR [95% CI]: 2.74 [1.05-7.15]; p = 0.039, and 3.04 [1.32-7 .04]; p = 0.009, respectively). These observations were consistent when data were interpreted using the p-value range between 0.1 and 0.001 (Supplementary Table 5 ).
Changes in SF-36 PCS & MCS scores
The results of this analysis are shown in Supplementary Table 6 . In the sensitivity analysis, there was no difference in SF-36 PCS scores between infliximab and secukinumab at week 14/16 (placebo-adjusted) and subsequent time points during the non-placebo-adjusted period. At week 24 (non-placebo-adjusted), there was evidence of improvements in non-placebo-controlled SF-36 MCS scores with secukinumab 150 mg compared with infliximab (mean CFB [95% CI]: 6.8 [1.6-6.2] vs 3.9 [5.6-8.0]; p = 0.032). No differences between treatments were evident at weeks 14/16 (placebo-adjusted) and 54/52 (nonplacebo-adjusted). These observations were consistent when data were interpreted using the p-value range between 0.1 and 0.001 (Supplementary Table 6 ).
Discussion
This study uses MAIC to assess the comparative effectiveness of the IL-17A inhibitor secukinumab (at two clinically relevant subcutaneously administered dosages: 150 mg and 300 mg) and the TNFi infliximab, intravenously administered, in TNFi-naive patients with active PsA [14, 32] . Although the RCTs from which the data were taken were conducted at different times, the key features of the study designs were very similar. By allowing matching of populations according to baseline characteristics, the MAIC methodology was able to adjust for the differences in patient populations between the earlier study on infliximab and the later studies on secukinumab.
In our MAIC, no differences in ACR responses were observed between secukinumab and infliximab during the first 14 weeks. Advantages in favor of secukinumab were seen after 24 weeks of treatment, in terms of ACR 20/50 responses, when compared with infliximab. This is in agreement with a recent MAIC analysis suggesting that patients with PsA receiving secukinumab are more likely to achieve higher mid-to long-term ACR responses than those treated with the TNFi adalimumab [17] .
The results of our principal analysis are largely supported by the sensitivity analyses, which used three additional matching variables (duration of PsA, SJC and CRP levels) for increased matching stringency. However, we acknowledge that findings not replicated in both analyses, such as SF-36 PCS, should be treated with caution when drawing conclusions, because it is possible these do not reflect true differences in treatment effects.
In this study, we include binary (ACR) and continuous (SF-36 scores) outcomes, in line with OMERACT [29] and GRAPPA guidance [30] . Our analyses comply with recent recommendations on the application of MAIC methodology [14, 15] , employing linear predictor scales such as ORs instead of comparing natural outcomes such as ACR 20 responses.
Health-related quality of life data are crucial for understanding how the clinical success of any therapy impacts patients' well-being and their ability to function in daily life. Evidence of a greater improvement in SF-36 PCS scores with infliximab than secukinumab 150 and 300 mg at week 14/16 was not observed at later time points, or replicated in the sensitivity analysis. It is worth noting that patients in the IMPACT 2 study had substantially lower SF-36 PCS scores at baseline than patients in FUTURE 2 or FUTURE 3, which may increase the chances that larger post-baseline changes would be reported.
The MAIC methodology has limitations. Although observed patient variables at baseline can be matched, it is not possible to control for unobserved variables or variables reported in only one study. Results are also most future science group www.futuremedicine.com relevant to patients similar to the matched IMPACT 2 trial population, namely TNFi-naive. Furthermore placebo adjustment was feasible only until week 16 owing to differences in study designs, and week 24 was the only common time point at which outcomes were reported in both RCTs. Although non-placebo-adjusted comparisons are a legitimate means of comparing treatments using long-term data, adjustments cannot be made for unobserved differences in trial populations or study design. A key difference in study design that could not be matched for both placebo and active treatment arms is route of administration, which may have led to differences in placebo responses. The reduced ESS for secukinumab must be acknowledged when interpreting our findings, although we have made an effort to counteract this by using pooled IPD from FUTURE 2 and FUTURE 3, which resulted in an acceptable sample size.
Conclusion
Our findings indicate that TNFi-naive patients with PsA have a similar probability of achieving ACR responses with subcutaneous secukinumab or intravenous infliximab in the short term. In the same target population, our findings indicate that there is a slightly higher probability of mid-to long-term ACR responses in those receiving secukinumab rather than infliximab. This study should be treated as an interim comparison in the absence of a confirmatory H2H RCT, and does not replace RCTs powered for a direct comparison between treatments. In future, such discussions can inform the design of potential H2H RCTs between PsA treatments.
Summary points
• In the absence of a head-to-head randomized controlled trial, matching-adjusted indirect comparison was used to compare subcutaneous secukinumab with intravenous infliximab in biologic-naive patients with psoriatic arthritis (PsA).
• Individual patient data from the FUTURE 2 and FUTURE 3 trials were matched to data from the IMPACT 2 trial using key patient demographic and clinical characteristics. Logistic regression determined matching weights for these variables.
• The relevant population in this comparison was TNFi-naive patients with characteristics similar to patients in the IMPACT 2 trial.
• Recalculated secukinumab outcomes were compared with infliximab outcomes at weeks 6/8 and 14/16 (both placebo-adjusted) and at weeks 24 and 54/52 (both non-placebo-adjusted).
• In terms of American College of Rheumatology (ACR) responses, there were no differences between secukinumab and infliximab in the short term (weeks 6/8 and 14/16).
• At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab.
• At weeks 54/52, ACR 20/50 responses were higher with secukinumab 300 mg than infliximab.
• TNFi-naive patients with PsA have a similar probability of achieving ACR responses with subcutaneous secukinumab or intravenous infliximab in the short term.
• In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving infliximab. Future perspective • Head-to-head trials in PsA are being conducted to provide direct comparisons of treatments. Before these RCT data are available, indirect treatment comparisons can provide interim data and inform trial design.
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